विवरण
Clinical trial landscape for curcumin in cognitive decline and dementia is reviewed, noting dose ranges, formulations, and preliminary outcomes.
Figure 10
Source Paper
Curcumin and Its Derivatives as Theranostic Agents in Alzheimer's Disease: The Implication of Nanotechnology.Cite This Figure
![Figure 10: Clinical trial landscape for curcumin in cognitive decline and dementia is reviewed, noting dose ranges, formulations, and preliminary outcomes.]() > Source: Umair Shabbir et al. "Curcumin and Its Derivatives as Theranostic Agents in Alzheimer's Disease: The I." *International journal of molecular sciences*, 2020. PMID: [33375513](https://pubmed.ncbi.nlm.nih.gov/33375513/)
<figure> <img src="" alt="Clinical trial landscape for curcumin in cognitive decline and dementia is reviewed, noting dose ranges, formulations, and preliminary outcomes." /> <figcaption>Figure 10. Clinical trial landscape for curcumin in cognitive decline and dementia is reviewed, noting dose ranges, formulations, and preliminary outcomes.<br> Source: Umair Shabbir et al. "Curcumin and Its Derivatives as Theranostic Agents in Alzheimer's Disease: The I." <em>International journal of molecular sciences</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33375513/">33375513</a></figcaption> </figure>